Start here if you're new
what it is
Mustang Bio is trying to turn engineered immune cells into treatments for hard-to-treat cancers and autoimmune disease.
how it gets paid
Last year Mustang Bio made n/a in revenue. Autoimmune CAR-T was the main engine at $0M, or 25% of sales.
what just happened
The latest quarter still showed a -$0.32 EPS, and the annual loss picture is still ugly.
At a glance
C+ balance sheet — struggling to keep the lights on
35/100 earnings predictability — expect surprises
-$38.57 fy2024 eps est
1.5 beta
~$7M market cap
xvary composite: 29/100 — weak
What they do
Mustang Bio is trying to turn engineered immune cells into treatments for hard-to-treat cancers and autoimmune disease.
Mustang does not need a giant lab to keep going. It licenses (borrows rights to the science) and works with 3 partner institutions: City of Hope, Fred Hutchinson, and Nationwide Children’s Hospital. That keeps fixed costs lighter than a big drug maker. It also means your upside depends on partners doing the hard science.
How they make money
n/a
annual revenue
Autoimmune CAR-T
$0M
Hematologic malignancy CAR-T
$0M
Solid tumor CAR-T
$0M
Licensing and research rights
$0M
The products that matter
lead clinical program
MB-106
CD20-targeted CAR-T
This is the program doing most of the equity-story work. The page does not give response-rate data, so the honest read is simple: you are waiting on evidence, not debating a mature franchise.
main catalyst
funding capacity
cash runway
C+ balance sheet
The balance sheet is rated C+, which is weak for a company with no product revenue. In human-speak: the science needs time, and time costs money.
survival metric
portfolio depth
pipeline optionality
thin on this page
Every biotech wants to be more than one program. This snapshot does not show enough validated depth to make that the thesis. For now, diversification is a hope, not a number.
unproven backup
Key numbers
$0.96
share price
You are paying 96 cents for a company with no reported revenue and a huge loss forecast.
-$38.57
2024 EPS
That is the projected annual loss per share. It is larger than the stock price by a mile.
5/100
price stability
A 5 out of 100 stability score means the shares can lurch on tiny news. That is a trading problem.
1.5
beta
A beta of 1.5 means the stock has tended to move 50% more than the market.
Financial health
C+
strength
- balance sheet grade C+ — weak — may struggle to fund operations
- risk rank 5 — safer than 5% of stocks
- price stability 5 / 100
C+ — below average. watch for debt servicing and cash burn.
Total return vs. market
Return history isn't available for MBIO right now.
source: institutional data · return history unavailable
What just happened
missed estimates
The latest quarter still showed a -$0.32 EPS, and the annual loss picture is still ugly.
EDGAR shows latest-quarter EPS of -0.32. Yahoo Finance shows trailing EPS of -0.28, so both sources point to a small but still negative earnings base. ’s FY2024 EPS history also shows a big improvement from -300.00 in 2023 to -38.57 in 2024.
$0M
revenue
-$0.32
eps
-$38.57
fy eps
the number that mattered
The latest-quarter EPS of -0.32 matters because it is still negative, even after the annual loss estimate improved from -300.00 in 2023 to -38.57 in 2024.
source: EDGAR, Yahoo Finance consensus, and, 2024-2025
Get this snapshot in your inbox
This page, delivered free — plus weekly updates when the numbers change. plain english, no spam.
weekly updates
earnings alerts
plain english
no spam
What could go wrong
the #1 risk is MB-106 failing to produce data strong enough to justify more funding.
med
MB-106 disappoints
This company does not have much diversification on the page. If the lead program stumbles, the stock does not have a steady commercial business to catch it.
The impact is simple: the current equity story gets repriced around what is left, and there may not be much left for investors to underwrite.
med
cash burn forces dilution
Pre-revenue biotech usually solves time with money. If trial timelines stretch or data are not clean enough to raise capital on decent terms, existing holders pay for that through dilution.
This matters more here because the market cap is only about $7M. Small raises can still be painful when the starting base is this small.
med
thin analyst and institutional support
Target data is thin and institutional activity is described as thin and noisy. That means there are fewer external anchors when sentiment turns.
In practice, the stock can swing on scarce information, and price moves can outrun the underlying fundamental change.
Stack those together and you get the real risk picture: if MB-106 slips and fresh capital arrives at a weak price, holders absorb the damage twice — first through sentiment, then through share count.
source: institutional data · regulatory filings · risk analysis
Pay attention to
calendar
the next clinical update
You are waiting for anything that sharpens the MB-106 timeline. In this stock, timing is not filler. It is the thesis clock.
risk
any sign financing comes before stronger data
If capital arrives before the story improves, the market will read that as urgency, not strength. That is usually bad for the price and worse for existing holders.
metric
35/100 earnings predictability
That score is low because the business still lacks operating stability. If it falls from here, uncertainty is getting worse, not better.
trend
whether the stock stops living at the low end of its range
The 52-week range is $1–$7 and the stock is at $0.96. That tells you sentiment has already been cut down hard. A durable recovery needs better evidence, not just a bounce.
Analyst rankings
short-term outlook
mixed
analyst target data is thin here. in human-speak: there is no clean consensus to hide behind.
risk profile
volatile
beta is 1.5 and price stability is 5/100. translation: this name has moved harder than the market and done it without much grace.
chart momentum
catalyst-driven
This stock trades more on trial headlines and financing expectations than on clean technical trends. You are buying event risk, not smooth momentum.
earnings predictability
35/100
That score is low because the underlying business is not stable yet. No product revenue means the operating picture can change fast.
source: institutional data
Institutional activity
institutional ownership data for MBIO is being compiled.
source: institutional data
Price targets
3-5 year target range
n/a
n/a
$1
current price
n/a
target midpoint · n/a from current
Want the deeper analysis?
The full deep dive: dcf model, scenario analysis, competitive moat breakdown, and quarterly tracking — everything on this page, taken further.
see plans from $5/moThe deep dive